Radioactive antibody before stem cell transplant for myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase study tests an injected radioactive antibody (211At-OKT10-B10) given before donor stem cell transplant, alone or with chemotherapy and low-dose body radiation. It is meant for people with high-risk multiple myeloma to see if the treatment can better prepare the body for the transplant and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that is newly diagnosed, or has come back (relapsed) or not responded (refractory)
- Your myeloma must be “high-risk” by specific lab/genetic findings (for example, certain chromosome changes) or certain disease history/types
- You must have an eligible donor for a stem cell transplant (matched related or unrelated donor), or a specific matching pattern if not
- You must plan to receive the radioactive antibody within 40 to 180 days after your autologous transplant (your own stem cells)
- Your body functions must be strong enough for treatment: kidney, liver, and heart/lung measurements within required limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
This trial tests a stem cell transplant using a donor's cells (allogeneic transplant) to treat high-risk multiple myeloma that has returned or not responded to treatment. It aims to replace the diseased bone marrow with healthy donor cells that can fight the cancer.
This Phase 2 trial tests whether a combination of anti-myeloma medicines given before stem cell transplant works well and is safe for people with multiple myeloma who also have kidney problems. It may help control the myeloma and prepare you for the transplant.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.